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Abstract
Background: Human T-cell leukemia virus type 1 (HTLV-1) causes adult T -cell leukemia (ATL)
but the expression of HTLV-1 is strongly suppressed in the peripheral blood of infected people.
However, such suppression, which may explain the long latency in the development of ATL, is
readily reversible, and viral expression resumes quickly with ex vivo culture of infected T -cells. To
investigate the mechanism of in vivo -specific transcriptional suppression, we established a mouse
model in which mice were intraperitoneally administered syngeneic EL4 T -lymphoma cells
transduced with a recombinant retrovirus expressing a GFP-Tax fusion protein, Gax, under the
control of the HTLV-1 enhancer (EL4-Gax).
Results: Gax gene transcription was silenced in vivo but quickly up-regulated in ex vivo culture.
Analysis of integrated Gax reporter gene demonstrated that neither CpG methylation of the
promoter DNA nor histone modification was associated with the reversible suppression. ChIP-
analysis of LTR under suppression revealed reduced promoter binding of TFIIB and Pol-II, but no
change in the binding of CREB or CBP/p300 to the viral enhancer sequence. However, the
expression of TORC2, a co-activator of CREB, decreased substantially in the EL4-Gax cells in vivo,
and this returned to normal levels in ex vivo culture. The reduced expression of TORC2 was
associated with translocation from the nucleus to the cytoplasm. A knock-down experiment with
siRNA confirmed that TORC2 was the major functional protein of the three TORC-family proteins
(TORC1, 2, 3) in EL4-Gax cells.
Conclusion: These results suggest that the TORC2 may play an important role in the in vivo -
specific transcriptional control of HTLV-1. This study provides a new model for the reversible
mechanism that suppresses HTLV-1 expression in vivo without the DNA methylation or
hypoacetylated histones that is observed in the primary cells of most HTLV-1 -infected carriers and
a substantial number of ATL cases.
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Human T-cell leukemia virus type 1 (HTLV-1), a life-long
persistent CD4+T -lymphotropic retrovirus, causes an
aggressive mature T -cell malignancy termed "adult T-cell
leukaemia" (ATL) [1,2] and an inflammatory disease of
the central nervous system known as HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP)
[3,4]. HTLV-1 infects 10–20 million people worldwide;
2–3% of infected individuals develop ATL, and a further
0.25–3% develop HAM/TSP.
Tax protein, encoded by the HTLV-1 pX region [5], is
closely associated with the development of these diseases
by triggering in a pleiotropic manner viral transcription
[6-9] and by deregulating the expression of cellular genes
[10,11]. However, the expression of viral genes, including
Tax, is almost completely suppressed in the peripheral
blood of infected people [12]. This may explain the long
latency in the development of ATL and other HTLV-1
related diseases. It has been assumed that there is a spe-
cific mechanism for this in vivo -specific suppression,
because gene expression of HTLV-1 in peripheral blood
cells from infected people, with the exception of two-
thirds of ATL patients [13], resumes quickly when the
infected cells are moved to in vitro conditions, without any
stimulation [12]. Such reversible control of the gene
expression should benefit HTLV-1 because Tax protein
harbors several strong epitopes for cytotoxic T -cells [14].
Thus, the transient expression of Tax is essential for the
propagation of viral infection and/or infected cells under
strict surveillance by the host immune system [15], the
efficiency of which may vary among individuals [16]. In
contrast, evading the suppressed state leading to the reac-
tivation of viral gene expression may be a key step in the
development of HTLV-1 associated diseases.
DNA methylation accumulated in HTLV-1 5'-LTR silences
viral gene transcription in leukemic cells [13,17]. How-
ever, further analysis revealed that viral gene transcription
is silenced in most carriers, and in about 20% of ATL
cases, despite no or only partial methylation of the 5'-LTR
[18]. Furthermore, in the case of ATL, transcriptional
silencing was observed regardless of the acetylation of his-
tones H3 and H4, markers of active transcription, in the
5'-LTR [18]. Thus, a reversible mechanism that suppresses
viral gene transcription without DNA methylation or
hypoacetylated histones in 5'-LTR has been postulated but
remains to be clarified.
As observed in other retroviruses, transcription of HTLV-1
is under the control of an enhancer/promoter located in
its LTR. The U3 region in the HTLV-1 LTR harbors an
enhancer element consisting of three 21 -bp direct repeats
that are activated exclusively in the presence of Tax. In the
center of each 21 -bp enhancer sequence there are Tax-
responsive elements (TRE) or viral cyclic AMP response
elements (CRE) [9,19], to which a variety of enhancer
binding proteins, including members of the CREB/ATF
family, bind, with or without Tax protein [20]. Among
them, CREB has been implicated as the primary player in
both basal and Tax-activated HTLV-1 transcription
[21,22]. CREB stimulates HTLV-1 viral transcription by
binding to the viral CRE and interacts with Tax, which is
also associated with the GC-rich sequences immediately
flanking the viral CRE, and recruits CBP/p300 to form a
Tax/CREB/CBP/p300/DNA quaternary complex [23,24].
In contrast, proteins belonging to another recently identi-
fied family of CREB cofactors, termed "transducers of reg-
ulated CREB activity" (TORCs) [25,26] have been
suggested to enhance HTLV-1 transcription, alone or in
combination with Tax, in a CREB-dependent manner in
vitro [27,28]. TORCs were originally found in the CREB -
dependent, but pCREB(phosphor-CREB)-independent,
activation of cellular genes [26]. The recruitment of
TORCs to the promoter does not appear to modulate
CREB DNA binding activity, but rather enhances the inter-
action of CREB with the TAFII130 component of TFIID
[26]. Among three members of the TORC-family protein,
the activity of TORC2 is tightly regulated by phosphoryla-
tion at Ser 171, which promotes the export of the protein
into the cytoplasm and its degradation [29].
To gain insights into the mechanism of this in vivo -spe-
cific transcriptional suppression, we established a mouse
model in which mice were intraperitoneally administered
syngeneic EL4 T -lymphoma cells transduced with a
recombinant retrovirus expressing GFP-Tax fusion protein
under the control of the HTLV-1 enhancer (EL4-Gax). Gax
protein retains the properties of Tax as a transcriptional
transactivator and also as an antigen, providing epitopes
for CTL [30]. Furthermore, Gax expression in EL4-Gax
cells is suppressed in vivo but is quickly up-regulated in ex
vivo culture, thus modeling the activity of HTLV-1 -
infected cells in asymptomatic carriers [30]. The present
study analyzed epigenetic modifications and factors in the
integrated HTLV-1 promoter/enhancer in EL4-Gax cells in
vivo as well as ex vivo. We found that reduced expression of
TORC2, but not of CREB or its phosphorylated form
(pCREB), was responsible for the suppression of viral
gene expression in vivo.
Results
Gax expression in vivo was suppressed at the level of 
transcription
EL4-Gax cell was established by transducing with an MLV-
based retrovirus vector expressing the GFP-fused Tax
(Gax), in which the U3 region of the 3' LTR was replaced
by that of HTLV-1 to ensure the Tax-dependent transcrip-
tional control of HTLV-1 (Fig. 1A), and the characteristicsPage 2 of 16
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retained as previously reported [30]. Expression of Gax
gene under the control of HTLV-1 LTR in EL4-Gax cells
grown in the peritoneal cavity of mice and cultured in vitro
was directly monitored by the intensity of GFP fluores-
cence using a fluorescent-activated cell sorter (FACS). This
demonstrated the in vivo -specific suppression of Tax
expression (Fig. 1B) [30].
Immunoblot analysis confirmed that in vivo protein
expression of Gax was abolished in cells, and the expres-
sion was reactivated in ex vivo culture (Fig. 1C, Gax). The
reduction of Gax protein is not simply due to a severe
growth condition inducing cell death since the proteolytic
cleavage of poly(ADP-ribose) polymerase, which is
known to be a sensitive marker of apoptosis [31] and
necrosis [32], was not observed (Fig. 1C, PARP).
The expression of Gax mRNA was analyzed using quanti-
tative reverse transcription polymerase chain reaction
(RT-PCR) to determine whether the suppression of Tax
expression was controlled at the level of transcription (Fig.
1D). The transcriptional suppression in vivo is specific for
the Gax gene because no suppression was observed in the
expression of cellular genes such as EF1-a, GAPDH, β-
actin, 18S-ribosomal RNA and endogenous retrovirus. On
the contrary, gene expression of CD4 was upregulated in
vivo, while it was silenced in EL4-Gax cells grown in vitro.
Real-time PCR analysis of Gax cDNA prepared from total
RNA in EL4-Gax cells demonstrated that the expression of
Gax mRNA was reduced in vivo and recovered after ex vivo
culturing to a level comparable with that before peritoneal
inoculation of the cells. Thus, Gax expression in vivo was
suppressed transcriptionally.
CpG methylation is not associated with the suppression of 
the Gax gene
Because complete- or hyper- methylation of cytosine resi-
dues at the CpG sites in the promoter region of the HTLV-
1 5'-LTR is associate with transcriptional suppression in
infected cell lines, the level of CpG methylation in the LTR
U3 region at 5' site of Gax-reporter genome was examined
in EL4-Gax cells. There are 11 possible CpG methylation
sites in the U3 region of HTLV-1, but only low levels of
methylation were observed in four independent experi-
ments. Although one case (experiment 1 in Fig. 2) showed
heavy methylation at a single CpG site in EL4-Gax cells in
vivo, little or no methylation was detected at this site in the
other experiments. In the other three experiments, less
methylation was observed in EL4-Gax cells in vivo (where
Gax expression was suppressed) than in cells grown in
vitro or ex vivo. Thus, no CpG methylation specific and
consistent with that in the in vivo cells was detected (Fig.
2). These results indicate that the suppression of Gax gene
expression in vivo is not explained by CpG methylation in
the enhancer sequence, suggesting the involvement of
other mechanism(s). This is consistent with a previous
analysis in which no or partial methylation was associated
with silencing in the peripheral blood cells of HTLV-1 car-
riers, as well as in significant number of ATL cases,
whereas transcriptional suppression of HTLV-1 in ATL cell
lines and some ATL leukemic cells was explained by
hypermethylation of the 5'-LTR [18].
Binding of CREB and pCREB to the HTLV-1 enhancer
CREB has been implicated as the primary player in both
basal and Tax-activated HTLV-1 transcription [24]. CRE-
dependent transcription is generally explained by the
recruitment of histone acetylating proteins, CBP/p300, to
the enhancer region of genes through an interaction with
CREB protein, which binds to the CRE sequence, and
acetylation of histones, opening the chromatin and pro-
A mouse model system with EL4-Gax cellsFigure 1 (see previous page)
A mouse model system with EL4-Gax cells. A. The structural organization of the R3Gaxbsr genome in EL4-Gax cells 
[29]. The EGFP coding sequence was fused with tax cDNA at the 5'-end, resulting in Gax. The Gax gene was linked with a drug 
resistance gene, bsr, by an internal ribosome entry site (IRES). The U3 region in the MLV LTR was replaced with that in the 
HTLV-1 LTR. 1 × 106 of EL4-Gax cells cultured in vitro (in vitro, a) were injected into peritoneal cavity of a syngenic C57BL/6J 
mouse. 3 weeks after challenge, cells were collected from ascitic fluids (in vivo, b) and transferred to the in vitro culture condi-
tion for 48 hours (ex vivo, c). B. Left, the expression of Gax protein in living cells was monitored as the intensity of GFP fluores-
cence by fluorescent-activated cell sorter (FACS); Right, statistical analysis of the GFP mean fluorescent intensity (GFP mfi), 
after deducting EL4 cells background level. EL4, parent cell line. C. Left, cell lysates were subjected to Western blot analysis 
with anti-Tax serum, PARP, an indicator of apoptosis or necrosis exhibiting the signature 89 kDa or 50 kDa fragment respec-
tively to see if the in vivo cells were healthy or not, or anti-β-actin antibody as loading control; Right, quantification of Gax and 
normalized to β-actin with a densitometry software program (NIH-image). D. Left, RT-PCR analysis of several viral and cellular 
mRNAs.; Right, Real-time PCR analysis of Gax mRNA expression and normalized to 18S ribosomal RNA in EL4-Gax cells with 
SYBR Green. Error bars indicate SEMs. Data were obtained from four independent experiments analyzing one mouse per 
experiment, and statistical analysis of the data was performed between the in vivo or ex vivo against the in vitro. *; p < 0.01. **; p 
< 0.05.Page 4 of 16
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CpG methylation of the enhancer/promoter region of provirus DNA in EL4-Gax cellsFigure 2
CpG methylation of the enhancer/promoter region of provirus DNA in EL4-Gax cells. Top: locations of CpG sites 
(#1–11) in the HTLV-1 U3 region studied in this experiment. The sense primer is complementary to the mouse genomic 
sequence flanking the 5'-LTR of provirus at the integration site, and the anti-sense primer is complementary to the junction 
sequence between the HTLV-1 and MLV U3 regions. The three 21 -bp enhancer sequences are indicated as boxes. Bottom: 
results of bisulfite genomic sequencing analysis of four independent experiments. Methylated and unmethylated CpG sites are 
expressed as filled and open rectangles, respectively. Amplified PCR products were subcloned into pGEM-T vector, and the 
nucleotide sequences of at least 13 clones were determined. GFP mfi: the GFP mean fluorescent intensity of EL4-Gax cells 
used for bisulfite genomic sequencing analysis.












































Retrovirology 2009, 6:73 http://www.retrovirology.com/content/6/1/73viding access to basic transcriptional factors including
RNA polymerase. Thus, since the reduction of recruitment
of either factor to the promoter region might result in the
suppression of transcription, a chromatin immunoprecip-
itation (ChIP) assay was used to analyze the binding of
these factors to the U3 region of the 5'-LTR.
Enhancer binding of CREB and pCREB was first examined
in EL4-Gax cells either in vivo (b) or under in vitro (a) cul-
ture conditions. As shown in Figure 3B (lanes 7–10), no
significant difference was observed in the amount of
CREB or pCREB in complex with the enhancer DNA at the
5'-LTR of the provirus. CBP functions as a cofactor by
being tethered to DNA through either pCREB or CREB, in
association with Tax, to acetylate histone proteins. Bind-
ing of CBP to the HTLV-1 enhancer was observed but
showed a similar intensity of protein binding (Fig. 3B,
lanes 11, 12).
As Gax is expressed in EL4-Gax cells in vitro, it was of inter-
est whether Gax is associated with the enhancer DNA.
ChIP assay was performed with antibody against GFP,
which recognizes the Gax protein. Consistent with the
protein expression, Gax was associated with the enhancer
DNA in EL4-Gax cells grown in vitro (lane 15) but not in
in vivo cells (lane 16), where the expression of Gax protein
was decreased. Tax recruits CBP to the HTLV-1 enhancer
by tethering with CREB at the CRE sequence; however, the
enhancer binding of CBP remained unchanged in the
absence of Tax (Fig 3B, lane 11, 12). In this respect, it is
noteworthy that phosphorylation of CREB protein, which
leads to a complex formation between CREB and CBP, is
increased in EL4-Gax cells grown in vivo (Fig 3C). Thus,
pCREB seems to be involved in the sustained enhancer
binding of CBP in the absence of Tax.
Although the amount of pCREB was increased in EL4-Gax
cells grown in vivo, no significant difference was observed
in the amount of pCREB binding to the enhancer DNA in
cells either in vivo or under in vitro culture conditions.
Since pCREB has been demonstrated to preferentially
bind to the enhancer sequence of HTLV-1 in a complex
with Tax [33], Tax might have selectively incorporated
pCREB in the complex.
Modifications of histones H3 and H4
Activated transcription is associated with histone acetyla-
tion in the chromatin of the respective genes; thus, his-
tone acetylation at the promoter region of the provirus
was analyzed using a ChIP assay, with antibodies against
acetylated histones H3 and H4. Unexpectedly, this analy-
sis revealed that histones at the LTR of the HTLV-1 provi-
rus were equally acetylated in EL4-Gax cells (Fig. 3D, lanes
11–14), either in vivo (b) and in vitro (a), whereas RNA
expression from the HTLV-1 promoter in these cells dif-
fered substantially (Fig. 1). Methylation of histone H3 at
the lysine residue was also analyzed, because this methyl-
ation is closely linked with transcriptional activation.
However, no change was observed in the methylation of
histone H3 in the promoter region of the provirus (Fig.
3D, lanes 15–16). Thus, the in vivo -specific transcrip-
tional repression of the HTLV-1 promoter was not associ-
ated with an altered level of chromatin modification.
These results are consistent with the previous finding that
gene silencing of HTLV-1 in an ATL case was observed
regardless of hyperacetylation of histones H3 and H4 in
the promoter [18].
Recruitment of basal transcription machinery to the 
proviral promoter
The recruitment of RNA polymerase II (Pol-II) and TFIIB,
a key general transcription factor in forming and stabiliz-
ing the early initiation complex [34], was analyzed to
determine whether suppression was present in the forma-
tion of the transcription initiation complex in the 5'-LTR
promoter. Although binding of TFIIB (Fig. 3D, lanes 9,
10) and Pol-II (Fig. 3D, lanes 7,8) to the constitutive pro-
moter of the EF-1a gene as positive controls was observed
equally in the ChIP assay, a substantial reduction in the
binding of these factors to the provirus promoter
sequence was detected under condition of suppressed Gax
expression in comparison with EL4 -Gax cells in the in
vitro culture (37 ± 5% for TFIIB and 47 ± 5% for Pol-II).
These results suggest that the loss of recruitment of basal
transcription factors is associated, at least in part, with the
suppression of Gax expression in vivo, regardless of the
constitutive binding of CREB-CBP/p300 to the enhancer
DNA.
Expression of TORC1 and TORC2 is repressed in EL4-Gax 
cells in vivo
In addition to the CREB-CBP/p300 pathway, another
family of CREB cofactors, TORCs, has been recently iden-
tified as activating CREB-dependent, but pCREB-inde-
pendent, transcription [25,26], including that of HTLV-1,
with or without Tax [27,28]. Thus, we next examined the
involvement of TORCs in transcriptional control in vivo.
The TORC family consists of three proteins, TORC1,
TORC2, and TORC3; expression of these proteins in EL4-
Gax cells was assessed by immunoblot analysis using anti-
bodies against each. All three TORC proteins were
detected in the cell lysate prepared from EL4-Gax cells, at
molecular weights of 75, 77/82, and 75 kDa respectively.
Consistent with previous reports, all TORC proteins
appeared to migrate as multiple bands, likely because of
they are phosphorylated. In particular, TORC2 protein
was composed of two distinct bands, of which the slower
migrating band was previously shown to be a phosphor-
ylated form of the faster migrating species. In fact, alkalinePage 6 of 16
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cells reduced the intensity of the slower migrating band
and resulted in the increase of the faster migrating band
(Fig. 4D).
When expression of the TORC proteins in EL4-Gax cells
grown in vitro, in vivo, and ex vivo was compared, the
amounts of TORC1 and TORC2 were reduced signifi-
cantly under in vivo growth conditions, and they recovered
to some extent upon their ex vivo culturing (Fig. 4A, B). In
contrast, the expression of TORC3 increased little, if any,
in in vivo or ex vivo conditions (Fig. 4C). Because a previ-
ous report demonstrated that the suppression of TORC1,
TORC2 or TORC3 expression by siRNA resulted in
reduced transcription from the HTLV-1 LTR [27], it seems
likely that reduced expression of TORC1 and/or TORC2 is
involved in the suppression of Gax gene expression in in
vivo conditions. It is noteworthy that the reduction of the
unphosphorylated TORC2 protein was more significant
than that of the phosphorylated form, because the former
is an active form of TORC2 retained in the nucleus.
Binding of TORC proteins to the HTLV-1 enhancer
As TORC proteins are recruited to enhancer DNA in com-
bination with CREB protein to activate CRE-dependent
transcription of HTLV-1, a ChIP assay was used to analyze
whether these proteins are associated with the U3 region
of the 5'-LTR in EL4-Gax cells grown in vitro and in vivo. As
shown in Figure 4E, recruitment of TORC2 and TORC3
proteins to the enhancer sequence was demonstrated in
EL4-Gax cells in vitro and both of the bindings were sub-
stantially reduced in in vivo cells, where little or no bind-
ing of TORC1 to enhancer DNA was observed. As judged
by densitometoric analysis, TORC2 appears to be the
main TORC protein that is associated with the enhancer
sequence of HTLV-1 in EL4-Gax cells, and the reduced
enhancer binding of TORC2 in cells grown in vivo was in
good agreement with the transcriptional suppression of
Gax in vivo.
TORC2 is primarily involved in the transcriptional control 
of the HTLV-1 promoter in EL4-Gax cells
To investigate which TORC protein functioned domi-
nantly in EL4-Gax cells, we analyzed Gax expression after
the knock-down of the three TORC genes by transducing
the cells with a retrovector for siRNA against each TORC
genes. Expression of siRNA resulted in the reduction of
the respective gene product by more than 50% (Fig. 5B)
but a significant reduction of Gax protein expression was
only observed in cells with the siRNA to the TORC2 RNA
(Fig. 5A, B). We, thus, concluded that TORC2 is primarily
involved in the transcriptional control of the HTLV-1 pro-
moter in EL4-Gax cells. Together, these results suggest that
the reduced TORC2 expression in EL4-Gax cells in vivo is
closely associated with the silencing of Gax gene expres-
sion in vivo.
Nuclear expression of TORC2 protein was reduced in EL4-
Gax cells in vivo
Phosphorylation of TORC2 protein by cellular kinases,
such as AMPK (AMP-activated protein kinase) kinase,
induces the translocation of TORC2 from the nucleus to
the cytoplasm, thereby suppressing CREB-dependent
transcription. In fact, the unphosphorylated form of the
TORC2 protein in vivo appeared to be reduced more sig-
nificantly than the phosphorylated form, when compared
in vitro or ex vivo by Western blotting (Fig. 4B). Therefore,
activity of AMPK was examined by measuring the phos-
phorylation at Thr172, which is required for AMPK activa-
tion [35]. The results shown in Figure 6C clearly
demonstrate the activation of AMPK activity in EL4-Gax
cells in vivo and its reduction in cells cultured ex vivo.
Subsequently, the subcellular localization of TORC2 in
EL4-Gax cells in vitro and in vivo was examined using
immunostaining (Fig. 6A). Consistent with the Western
blotting, expression of the TORC2 protein in in vivo cells
was greatly reduced in comparison with that in the in vitro
cultured cells, and the expression was restored after ex vivo
ChIP analysis of the enhancer/promoter region in Gax provirusFigure 3 (see previous p ge)
ChIP analysis of the enhancer/promoter region in Gax provirus. A. Schematic representation of the 5'-LTR in the 
R3Gaxbsr reporter gene. The three 21 -bp enhancer sequences (boxes), the TATA sequence, and the transcription start site 
(+1) are shown. Primers for PCR are indicated by arrows. The 5'- and 3'-ends of amplified DNA are denoted as the nucleotide 
positions relative to the transcription start site. Primers #1 and #2 amplify the enhancer region, and primers #3 and #4 amplify 
the promoter region of Gax-5'-LTR. B. Binding of CREB, phosphor-CREB and CBP to the Gax enhancer region was constant in 
EL4-Gax cells in vitro (a) and in vivo (b)(left), but the enhancer binding of Gax was reduced when EL4-Gax cells were grown in 
vivo (right). C. Expression of CREB protein in EL4-Gax cells. Anti-CREB1, anti-phosphor-CREB antibodies were used to detect 
proteins in EL4-Gax cells grown in vitro, in vivo, and ex vivo. Equivalent protein loading was confirmed by stripping and re-prob-
ing the blot with an anti-β-actin antibody. D. Binding of acetylated histone 3 at Lys-9, 14 (H3), acetylated histone 4 at Lys- 5, 8, 
12, 16 (H4) and trimethylated histone 3 at Lys-4 (H3K4tri) to the Gax enhancer region was not changed in EL4-Gax cells either 
in vitro (a) or in vivo (b), but the promoter binding of the basic transcription factor TFIIB and of RNA polymerase II (Pol-II) was 
reduced when EL4-Gax cells were grown in vivo. Factors binding to promoters of EF-1a and β-globin are presented as positive 
and negative controls, respectively.Page 8 of 16
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Expression of TORC proteins in EL4-Gax cellsFigure 4
Expression of TORC proteins in EL4-Gax cells. Anti-TORC1 (A), anti-TORC2 (B), and anti-TORC3 (C) antibodies were 
used to detect each protein in EL4-Gax cells grown in vitro, in vivo, and ex vivo. Equivalent protein loading was confirmed by 
stripping and re-probing the blot with an anti-β-actin antibody. Apparent molecular weights of marker protein are indicated. D. 
Phosphorylation of TORC2. Protein from EL4-Gax cells was incubated with or without rAPid Alkaline Phosphatase (see meth-
ods in detail). E. ChIP analysis of TORCs in EL4-Gax cells in vitro (a) and in vivo (b). Little or no binding of TORC1 and TORC3 
to the Gax enhancer region was observed in vitro (a) or in vivo (b), but the binding of TORC2 to the Gax enhancer region was 
high in vitro (a) and reduced when EL4-Gax cells were grown in vivo (b).
Retrovirology 2009, 6:73 http://www.retrovirology.com/content/6/1/73culture (Fig. 6A, "TORC2", and Fig. 6B). Furthermore, the
subcellular localization of TORC2 was restricted to the
cytoplasm of in vivo cells (Fig. 6A, "TORC2 + DAPI"),
whereas the protein was primarily expressed in the
nucleus in cells cultured in vitro and ex vivo (Fig. 6A, B).
Because cytoplasmic retention of TORC2 results in its deg-
radation by proteasomes, it appears that some in vivo -spe-
cific cellular signal(s) may induce the cytoplasmic
translocation, and thereby the degradation of the TORC2
protein, resulting in the suppression of HTLV-1 transcrip-
tion in EL4-Gax cells.
Discussion
Tax protein plays a key role in the development of ATL
and other HTLV-1-related diseases through pleiotropic
actions, that include transactivation of the NF-κB [36],
CREB [22,21,24], and SRF pathways [37,38]; transrepres-
sion of lck [39], p18 [40], DNA polymerase β [41], and
histone gene transcription [42]; and functional inactiva-
tion of p53 [43] and MAD1 [44]. However, the expression
of viral genes, including Tax, is strongly suppressed in the
peripheral blood of patients infected with HTLV-1 [12],
mainly because the Tax protein harbors several strong
epitopes for cytotoxic T -cells [14]. Such suppression is
readily reversible, because gene expression of HTLV-1 in
peripheral blood cells from infected people, with the
exception of two-thirds of ATL patients [13], quickly
resumes when the infected cells are moved to in vitro con-
ditions, without any additional stimulation [12]. This
indicates that the transient expression of Tax is essential
for the propagation of viral infection, and/or the infected
cells are under strict surveillance by the host immune sys-
tem [15].
DNA methylation is a host defense mechanism for inacti-
vating transposable elements, such as retroviruses, to
inhibit their transcription and their generation of new
viruses. Thus, the transcriptional silencing of the Tax gene
has been studied extensively in terms of DNA methylation
of the 5'-LTR, which is the promoter of viral transcription
[45,17,13,18]. In ATL-derived cell lines, complete- or
Effect of the knock-down of TORC genes on the expression of Gax in EL4-Gax cellsFigure 5
Effect of the knock-down of TORC genes on the expression of Gax in EL4-Gax cells. A. Expression of TORC pro-
teins and Gax in EL4-Gax cells transduced with retrovirus (for TORC1 and 3) or lentivirus (for TORC2) vectors encoding 
siRNA against each TORC gene. Expression of the siRNA resulted in the reduction of respective TORC proteins, but only 
siRNA to the TORC2 gene suppressed Gax gene expression. Proteins were detected with antibodies to the respective TORC 
proteins, Tax, or β-actin by the ECL or ECL plus system. B. Densitometric analysis data of TORC proteins and Gax protein 
normalized to β-actin are presented as mean ± SEM of three independent experiments. T1, TORC1; T2, TORC2; T3, TORC3.Page 10 of 16
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Expression and subcellular localization of TORC2 in EL4-Gax cellsFigure 6
Expression and subcellular localization of TORC2 in EL4-Gax cells. A. Immunofluorescent staining of TORC2 protein 
(red) in EL4-Gax cells grown in vitro, in vivo, or ex vivo. Cells were counterstained with DAPI (blue) to localize the nucleus and 
examined by confocal microscopy. The right panel shows a magnified image of a single cell indicated by an arrow in the adjacent 
panel. B. Statistical analysis of subcellular localization of TORC2 expression. The amount of protein expression was determined 
as the number of fluorescent pixels in the total and nucleus for each growth condition. Data were obtained by counting pixels 
in 108, 137, and 106 cells for in vitro, in vivo, and ex vivo conditions, respectively. Error bars indicate SEMs. *; p < 0.001. C. 
Expression of AMPKα protein in EL4-Gax cells. Anti-AMPKα and anti-phosphor-AMPKα (Thr172) antibodies were used to 
detect protein in EL4-Gax cells grown in vitro, in vivo, and ex vivo. Equivalent protein loading was confirmed by stripping and re-
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Retrovirology 2009, 6:73 http://www.retrovirology.com/content/6/1/73hypermethylation of CpG DNA in 5'-LTR is closely associ-
ated with the suppression of viral gene transcription, and
partial methylation is not sufficient to silence transcrip-
tion of the Tax gene [13,17]. In contrast, the 5'-LTR of the
provirus genome was found to be unmethylated or par-
tially methylated in about 70% of ATL leukemic cells with
intact provirus sequences [18], whereas Tax gene expres-
sion was mostly silenced in vivo. Furthermore, lack of
DNA methylation in the 5'-LTR was more frequently
observed in HTLV-1 carriers than in primary ATL cells
[18]. These data indicate that a mechanism other than
DNA methylation is involved in the silencing of Tax gene
transcription in the peripheral blood of HTLV-1 -infected
individuals in vivo. The mouse model system studied in
this report models gene control in HTLV-1 -infected cells
in ATL patients and carriers, where reversible silencing of
Tax gene transcription is observed, without extensive DNA
methylation of the 5'-LTR.
The transcription of HTLV-1 is controlled by CREB bind-
ing to the enhancer sequence, which consists of three 21-
bp direct repeats containing CREs in the middle. The viral
transactivator, Tax, interacts with both CREB and CBP/
p300 in a manner independent of the phosphorylation of
CREB and activates the HTLV-1 enhancer. In the current
study, approximately equivalent binding of CREB and
CBP on the enhancer DNA was observed in the Gax
expressing EL4-Gax cells cultured in vitro or EL4-Gax cells
grown in vivo, where Gax expression was substantially sup-
pressed (Fig. 3B and Fig. 1D). In addition, although his-
tone acetylation, a downstream effect of CREB-CBP/p300
association, remained constant, recruitment of the basic
transcription factor (TFIIB) and RNA polymerase II to the
promoter was diminished in cells grown in vivo (Fig. 3C).
These observations suggest that activation machinery
other than the CREB-CBP/p300 pathway might be
involved in the transcriptional control of HTLV-1 in vivo,
whereby constitutive association of CREB-CBP/p300 and
acetylated histones keeps the promoter in an inducible
condition. In this respect, it is noteworthy that reversible
silencing was observed in an ATL case regardless of hyper-
acetylation of histones H3 and H4 in the 5'-LTR [18].
CREB-dependent promoters have been thought to
respond to various intracellular and extracellular signals
via stimulus-dependent phosphorylation of CREB at Ser-
133 and the resulting recruitment of the co-activator par-
alogues, CBP and p300 [46]. Although a number of
growth factors and hormones trigger CREB phosphoryla-
tion with comparable stoichiometry and kinetics, they are
often ineffective in promoting transcription through the
CREB binding site. Furthermore, knock-in mice with
mutations in CBP/p300 that blocked the interaction with
phosphor-CREB showed only modest changes in cAMP-
dependent transcription. Thus, the involvement of addi-
tional CREB co-activators was postulated, and, subse-
quently, a new family of proteins has been identified as
co-activators independent of CREB phosphorylation
using high-throughput transformation assays [25,26]. The
novel co-activators, TORC 1–3, interact with the bZIP of
CREB in a phospho-Ser133-independent manner through
their N-terminal coiled-coil structure, leading to the acti-
vation of CREB -mediated transcription.
Accordingly, we examined the involvement of TORCs in
the regulation of HTLV-1 transcription in vivo and found
that expression of TORC1 and TORC2 in EL4-Gax cells
coincided with the suppressed expression of Gax in vivo
and its up-regulation in vitro or ex vivo. Previous reports
have demonstrated that the forced expression of human
TORC proteins activates the transcription of the HTLV-1
LTR, whereas depletion of TORCs by siRNA-mediated
knock-down impairs Tax-dependent and Tax-independ-
ent transcription [27,28]. We also observed the activation
of a luciferase reporter gene under control of HTLV-1 LTR
in association with the over-expression of TORC1,
TORC2, or TORC3 of mouse origin (data not shown). It
was recently reported that TORC3 repressed the transcrip-
tion of HTLV-1 by interacting with Bcl3, which, in turn,
recruits HDAC1 to deacetylate histones. However, such a
mechanism is likely not involved in the current system
because no significant change in the promoter association
of acetylated histones H3 and H4 was observed in cells
grown in vitro or in vivo, although the expression of
TORC3 appeared to increase slightly in vivo. In contrast,
depletion of TORC1 or TORC3 expression in EL4-Gax
cells by siRNA did not affect the expression of Gax,
whereas TORC2 knock-down resulted in a significant
reduction in Gax expression, although expression of
siRNA to any of the TORC genes reduced the amount of
the respective TORC proteins in EL4-Gax cells to about the
same extent. Consistently, the analysis of enhancer bind-
ing of TORC proteins by using a ChIP assay revealed that
TORC2 is the major binding factor among the three
TORC-family proteins in EL4-Gax cells (Fig. 4E). These
results indicate that TORC2 is primarily responsible for
the transcriptional control of HTLV-1 LTR in EL4-Gax cells
in vivo.
TORC2 activity is regulated by phosphorylation of the
protein, which induces the cytoplasmic translocation of
TORC2 from the nucleus, leading to its degradation by the
26S proteasome. In fact, we demonstrated that the activity
of AMPK, a family of Ser/Thr kinases, which phosphor-
ylates TORC2 [29,35], was activated in EL4-Gax cells in
vivo (Fig. 6C). In EL4-Gax cells cultured in vitro, most
TORC2 protein was localized in the nucleus where it
would be involved in the transcription of the provirus.
When the cells were grown in the peritoneal cavity of
mice, the nuclear expression of TORC2 was markedlyPage 12 of 16
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relatively constant. This result is consistent with the West-
ern blotting data, which showed that the amount of the
unphosphorylated form of TORC2 protein was more sig-
nificantly reduced in vivo than that of the phosphorylated
form (Fig. 4B). Together, these findings suggest that some
signal(s) specific for in vivo growth induces the phospho-
rylation of TORC2 protein, leading to the cytoplasmic
translocation and degradation of the protein. In this
respect, it is noteworthy that the activity of AMPK, is mod-
ulated by various pathological stresses and physiological
stimuli, including glucose deprivation, hyperosmotic
stress, heat shock, hypoxia, and ischemia [35]. In addi-
tion, calcium influx after hormonal stimulation or anti-
gen stimulation of lymphocytes induces calcineurin
activity, which in turn dephosphorylates TORC2. Thus,
various physiological and immunological signals can
induce the reactivation of provirus, even in vivo, through
modulation of TORC2 activity.
Conclusion
Using a mouse model system in which the transcriptional
control was quite similar to that in asymptomatic HTLV-1
-infected carriers [30], we demonstrated that TORC2, a
recently identified co-activator of CREB, is a key determi-
nant of HTLV-1 gene expression in vivo. An analysis of pro-
moter binding by transcriptional factors and chromatin
modifications in EL4-Gax cells revealed that neither CpG
methylation of the HTLV-1 LTR nor reduced association
of enhancer binding factors such as the CREB-CBP/p300
complex coincided with the in vivo -specific suppression
of HTLV-1 transcription. Instead, the expression of
TORC2 was coordinated with suppression in vivo and the
reactivation ex vivo of provirus transcription. In addition,
the transcriptional activities of the provirus gene in vivo
and in vitro were associated with the nuclear accumulation
of TORC2 protein, which is tightly controlled by phos-
phorylation of the protein in response to various physio-
logical signals.
Methods
Cell lines and animal model
The establishment of the EL4-Gax mouse model system
was previously reported [30]. Briefly, 1 × 106 EL4-Gax cells
were injected into the peritoneal cavity of 6-week-old
male C57BL/6J mice (Charles River Laboratories Japan,
Kanagawa, Japan) in 0.1 mL phosphate -buffered saline
(PBS). After three weeks, cells in ascitic fluids (in vivo cells)
were recovered and cultured in culture medium for 48 h
(ex vivo culture). Gax expression was monitored using a
FACS (Becton Dickinson, NJ) as the intensity of GFP fluo-
rescence. The mice were maintained under standard path-
ogen-free conditions in the animal facility of Kansai
Medical University, and the protocol for the experiments
was approved by the Institutional Animal Care and Use
Committee of Kansai Medical University.
Quantitative real-time RT-PCR analysis of Gax gene 
transcripts
Total RNA was extracted from cells using the Trizol rea-
gent (Invitrogen, Carlsbad, CA) and treated with RNase-
free DNase I (GIBCO BRL) at 37°C for 30 min, followed
by phenol-chloroform extraction and ethanol precipita-
tion. Total RNA (1 μg) was subjected to reverse transcrip-
tion using RivaTra Ace (Toyobo, Osaka, Japan) with
random 9 mer oligonucleotides (Takara, Kyoto, Japan) as
a primer.
Real-time PCR was performed in a 25-μL reaction mixture
consisting of 2-fold SYBR Green mastermix (Applied Bio-
systems, UK); 50 pg or 10 ng cDNA for 18S-rRNA or Gax,
respectively; 0.4 μM primer; and the BioRad-iQ-Real-Time
PCR Detection System. The cycling conditions for all
amplifications were 95°C for 15 min; 40 cycles of 95°C
for 30 s, 60°C for 30 s, and 72°C for 30 s, with a single
fluorescence measurement melting curve program (60–
95°C with a heating rate of 0.2°C per second and a con-
tinuous fluorescence measurement); and finally a cooling
step to 24°C. Each individual sample was run in triplicate
wells; the cycle threshold (Ct) of each well was recorded
at the end of the reaction. The Ct was manually set up at
the level that reflected the best kinetic PCR parameters,
and melting curves were analyzed. The average and stand-
ard deviation (SD) of the three Cts was calculated, and the
average value was accepted if the SD was less than 0.38.
The 2ΔΔCt method was used to analyze the relative
changes in Gax gene expression in in vivo or ex vivo sam-
ples with those in vitro.
The primers used for PCR were as follows: for the Gax
gene, 5'-ACGCCTATGATTTCCGGGCC-3' and 5'-GGA-
TATTTGGGGCTCATGGTCA-3'; for CD4, 5'-CAGAGCCT-
GACCCTGACCTTG-3' and 5'-
CATCACCACCAGGTTCACTTCC-3'; for endogenouse
mouse retroviral env, 5'-GAAGGTCCAGCGTTCT-
CAAAAT-3' and 5'-CACGTGATTTCACTTCTTCTGG-
3'[47]; for elongation factor (EF)-1α, 5'-TCTGGTT-
GGAATGGTGACAACATGC-3' and 5'-CCAGGAAGAGCT-
TCACTCAAAGCTT-3'; for GAPDH, 5'-
ACCACAGTCCATGCCATCAC-3' and 5'-TCCACCACCCT-
GTTGCTGTA-3'; for β-actin: 5'-GAGATCTGCCGATC-
CGCCGCCCG-3', and 5'-
GCTCGAGGTGTGCACTTTTATTCAACTGG-3'; for 18S-
rRNA, 5'-CTCGATTCCGTGGGTGGTGGTG-3' and 5'-
GGCCGATCCGAGGGCCTCAC-3'.
Western blot analysis
Cells were lysed and sonicated in cell lysis buffer (20 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM Na2EDTA, 1 mMPage 13 of 16
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plus complete proteinase inhibitor cocktail and phos-
phatase inhibitor mixture (Roche Applied Science, Indi-
anapolis, IN). Aliquots containing 5–30 μg of protein
were separated by SDS/polyacrylamide gel electrophore-
sis; transferred onto PVDF membrane (Immobilon-P, Mil-
lipore, Billerica, MA); and detected by the ECL or ECL plus
system (GE Healthcare, Buckinghamshire, UK). Used
antibodies were TORC2 rabbit polyclonal antibody
(#ST1099, Calbiochem, La Jolla, CA), TORC1 rabbit pol-
yclonal antibody (#2501), TORC3 rabbit polyclonal anti-
body (#2768), phospho-AMPKα (Thr172) rabbit
monoclonal antibody (40H9, #2535), AMPKα rabbit
monoclonal antibody (23A3, #2603, Cell Signaling Tech-
nology); CREB1 (#06–863), phospho-CREB (#06–519,
Upstate Technology, NY); PARP-1 mouse monoclonal
antibody (#611038, BD. Biosciences, San Jose, CA) or β-
actin mouse monoclonal antibody (clone AC-5, Sigma-
Aldrich, MO) and HRP-conjugated protein A for rabbit
primary antibodies or anti-mouse IgG-HRP (GE Health-
care) for mouse monoclonal primary antibodies.
Phosphatase treatment of protein from EL4-Gax
1 × 106 EL4-Gax cells were lysed in 250 μl of cell lysis
buffer (mentioned above, Cell Signaling Technology) and
1× complete protease inhibitor cocktail (Roche) with or
without phosphatase inhibitor cocktail (2.5 mM sodium
pyrophosphate; 1 mM β-glycerophosphate; 1 mM
Na3VO4; 50 mM sodium fluoride), plugged into liquid
nitrogen and thawed on ice immediately. Lysate was clar-
ified by centrifugation at 14,000 rpm for 10 minutes at
4°C. After measuring protein concentration, 20 μg pro-
tein was dispended to 1× rAPid Alkaline Phosphatase
buffer with or without phosphatase inibitor cocktail,
treated with or without 20 units of rAPid Alkaline Phos-
phatase (Cat No.04898133001, Roche) for 60 minutes at
37°C in a 100 μl reaction volumes. The 1/3 volume of
samples was then separated by SDS-PAGE.
Analysis of CpG methylation
Methylation of the cytosine residue at CpG sites was ana-
lyzed using the bisulfite genomic sequencing method [16]
with minor modifications. Briefly, 1 μg genomic DNA was
used for bisulfite treatment. The DNA sample in 0.2 N
NaOH was denatured at 37°C for 10 min, followed by
incubation at 50°C overnight in 2.6 M sodium bisulfite
and 0.5 mM hydroquinone (Sigma-Aldrich) solution. The
solution was then sealed with 200 μL mineral oil and kept
in the dark. Sample DNA was purified using the Wizard
DNA Clean-Up system (Promega, Madison, WI) and
treated with 0.3 N NaOH. DNA was precipitated with eth-
anol and dissolved in 50 μL H2O. Then 30% of this solu-
tion was subjected to PCR.
PCR was performed in 50-μL reaction mixtures containing
1 μL Acuprime Taq DNA polymerase and its buffer (Invit-
rogen) and a primer set at 0.2 μM. The primer sequences
to amplify the 5'-LTR HTLV-1 U3 region were sense
primer (complementary to the modified cellular flanking
region), 5'-CCTCCTATCAAAACTAACTTTAAC-3', and
antisense primer (complementary to the modified HTLV-
1 U3 region), 5'-AAGTTTTTTGAGGTGAGGGGT-3'.
The cycling conditions for all amplifications were 94°C
for 2 min; 40 cycles of 94°C for 30 s, 56°C for 30 s, and
68°C for 30 s; and a final extension at 68°C for 5 min. The
amplified PCR products, purified with the QIA quick PCR
kit (QIAGEN, Germantown, MD), were subcloned into a
pGEM-T easy vector (Promega), and the nucleotide
sequences of at least 13 clones were determined.
ChIP assay
ChIP assays were performed according to the manufac-
turer's protocol (Upstate Biotechnology, Lake Placid, NY)
with some modifications. Briefly, 2 × 106 cells were fixed
with 1% formaldehyde for 5 min at room temperature
and sonicated (Biorupter UCD-200T; CosmoBio, Tokyo,
Japan) to obtain on average 600 -bp length of soluble
chromatin. The chromatin solutions were pre-cleared
with 80 μL 50% Protein G Sepharose slurry (Amersham)
preabsorbed with 0.2 mg/mL sonicated salmon sperm
DNA and 0.05% BSA. After a 10-fold dilution with ChIP
dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl), 2 mL
pre-cleared complex was combined with 2–15 μg anti-
bodies against CREB1 (06–863), phosphor-CREB (06–
519), acetylated H3 at Lys-9, 14 (06–599), acetylated H4
at Lys-5, 8, 12, 16 (06–598, Upstate Technology), CBP
(sc369), TFIIB (sc-225), Pol-II (sc899, Santa Cruz Biotech-
nology, CA), methylated H3 Lys-4 (AB8580, Abcam Ltd.,
Cambridge, UK), GFP (mouse monoclonal antibody,
clones 7.1 and 13.1, Boehringer Mannheim), or normal
mouse IgG (I-5381, Sigma), rabbit IgG (011-000-002,
Jackson immunoresearch Laboratories, West Grove, PA)
and rotated at 4°C overnight. The immune complexes
were collected by incubating with 80 μL of protein G
slurry. DNA-protein cross-linking was reversed by incuba-
tion at 65°C overnight, and the samples were treated with
RNase A and then with proteinase K. After phenol extrac-
tion and ethanol precipitation, the DNA was finally dis-
solved into 30 μL of water.
The primers used for PCR were as follows. For the 5'-LTR
enhancer, sense primer, complementary to the 5'flanking
cellular region, 5'-AAGCACAGAAGACACCTTGTGCAC-3'
and antisense primer, complementary to 5'-LTR HTLV-1
U3 region, 5'-AAGTTTTTTGAGGTGAGGGGTTGTCG-3'.
5'-LTR promoter region, sense primer, complementary to
HTLV-1 U3/MLV U3 junction region, 5'-CATGGCACG-Page 14 of 16
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mentary to MLV gag region, 5'-
TCTCCCGATCCCGGACGAGCC-3'. The following
sequences of primers were used for other control gene
promoters: for EF1a, f (-20): 5'-CGAGGGTGGGGGA-
GAACGGTAT-3' and r (152): 5'-AGCTAATC-
CCCGCCGACGACAG-3'; for β-globin, f (-117): 5'-
ACCGAAGCCTGATTCCGTAGAGC-3' and r (+133): 5'-
CTCACCACCAACTTCATCGGAGTT-3'.
All PCRs were performed in 20-μL reaction mixes consist-
ing of 1–10 μL of the ChIP product, 1 U Ex Taq polymer-
ase (Takara), 200 mM each of deoxynucleoside
triphosphates, and a primer set at 0.4 μM. The cycling con-
ditions for all amplifications were 94°C for 5 min; 33–35
cycles of 94°C for 30 s, 62–68°C for 30 s, and 72°C for
30 s; and a final extension at 72°C for 5 min.
Immunofluorescent staining
Cells were grown in suspension or harvested from ascites
and were then fixed by adding an equal volume of 4%
paraformaldehyde diluted in PEM/PBS(-) buffer (1/5 vol-
ume of PEM [see below] and 4/5 volume of PBS(-)) for 30
min at 4°C, collected by centrifugation (300g, 3 min),
washed and resuspended in PBS(-), and then cytospun
(Shandon Cytospin3; 20,000 cells/slide, 700 rpm, 1 min)
onto 1 N HCl and 95% ethanol-washed slide glasses (Mat-
sunami, Osaka, Japan). The cells were washed twice with
PEM buffer (80 mM potassium PIPES [piperazine-N, N'-
bis(2-ethanesulfonic acid)] [pH 6.8], 5 mM EGTA [pH
7.0], 2 mM MgCl2) and permeabilized by incubation in
PEM/PBS(-) buffer containing 0.1% Triton X-100 for 30
min at room temperature and blocked with goat serum
(1:20 dilution in TBS containing 0.1% Tween-20) for 30
min at room temperature. After blocking, the cells were
incubated with anti-TORC2 antiserum ((#ST1099, Calbi-
ochem) or normal rabbit IgG for 3 h at room temperature
or overnight at 4°C in TBS containing 0.1% Tween-20
(TBS-T). Thereafter, the cells were washed three times with
TBS-T and incubated with Cy5-conjugated AffiniPure
donkey anti-rabbit IgG (#711-175-152, Jackson Immuno
Research Laboratories) in TBS-T. After 1 h, the cells were
washed three times in TBS-T. To visualize the nucleus, we
counterstained the cells with DAPI (4', 6'-diamidino-2-
phenylindole; Nacalai Tesque, Kyoto, Japan; final concen-
tration 0.4 μg/mL, 5 min incubation at room tempera-
ture) and washed them once with PBS(-), then mounted
them in mounting media and examined them with a Zeiss
LSM510 META microscope.
siRNA interference
TORC siRNA hairpin expression vectors (shTORC1 retro-
viral vector, #NM-001004062; shTORC3 retroviral vector,
#XM-344915; shTORC2 lentiviral vector, #NM-02881)
were purchased from Open Biosystems (Huntsville, AL).
Recombinant retroviruses for shTORC1 and shTORC3
were generated by transfecting respective retroviral vector
plasmids into BOSC23 cells, and recombinant lentivirus
expressing shTORC2 was generated in HEK293T cells by
the cotransfection of the lentiviral vector plasmid with
expression vectors for Gag/Pol (pGag/Pol), Rev (pRev),
and VSV-G protein (pVSV-G) using the Lipofectamine
2000 (Invitrogen) transfection reagent. Viral supernatant
was collected 48 h after transfection and added to EL4-
Gax cells for infection in the presence of polybrene (8 μg/
mL). Infected cells were selected with puromycin (4 μg/
mL), and mixtures of 40–200 clones of each virus were
used for further analysis.
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